Solvay To Co-Promote Wyeth’s Effexor XR With 120 Reps
This article was originally published in The Pink Sheet Daily
Executive Summary
Under the agreement, Wyeth will co-develop four mental health products from Solvay’s pipeline, including bifeprunox, an atypical antipsychotic in Phase III.